News BMS suffers further setback in lung cancer No fast approval for immunotherapy combo in first line use.
News AZ looks for advantage over Merck in lung cancer trial AZ rejigs endpoints in key trial of durvalumab
News Keytruda set for first line lung cancer use in EU MSD drug will not face competition from BMS rival in this use.
UK & Europe AA Gill takes swipe at NICE in final column NHS initially denied late writer immunotherapy.
News AZ's Tagrisso shines in lung cancer trial Phase 3 trial supports Tagrisso as "standard of care" for some patients
News Inflammation-focused Rezera sets terms for IPO Rezera, formerly known as NodThera, has announced the terms of its planned IPO, hoping to raise upwards of $200m for its NLRP3 inhibitor pipeline.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
